Cargando…
Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprot...
Autores principales: | Mizuno, Manami, Miyazawa, Ken, Tabuchi, Masako, Tanaka, Miyuki, Yoshizako, Mamoru, Minamoto, Chisato, Torii, Yasuyoshi, Tamaoka, Yusuke, Kawatani, Makoto, Osada, Hiroyuki, Maeda, Hatsuhiko, Goto, Shigemi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642347/ https://www.ncbi.nlm.nih.gov/pubmed/26561427 http://dx.doi.org/10.1038/srep16510 |
Ejemplares similares
-
β-carboline biomediators induce reveromycin production in Streptomyces sp. SN-593
por: Panthee, Suresh, et al.
Publicado: (2019) -
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
por: Watanabe, Keiichiro, et al.
Publicado: (2021) -
β-carboline chemical signals induce reveromycin production through a LuxR family regulator in Streptomyces sp. SN-593
por: Panthee, Suresh, et al.
Publicado: (2020) -
Inhibitory mechanism of reveromycin A at the tRNA binding site of a class I synthetase
por: Chen, Bingyi, et al.
Publicado: (2021) -
Author Correction: Inhibitory mechanism of reveromycin A at the tRNA binding site of a class I synthetase
por: Chen, Bingyi, et al.
Publicado: (2021)